Impact of a chemoresponse assay on treatment costs for recurrent ovarian cancer

[gdpawel]

The National Comprehensive Cancer Network (NCCN) updated the NCCN Clinical Practice Guidelines for Oncology to include the use of chemoresponse assays.

The NCCN states that chemoresponse assays are being used in some NCCN member institutions for decisions related to future chemotherapy in situations where there are muliple equivalent chemotherapy options available.

Recent studies presented at ASCO and published in the International Journal of Gynecologic Cancer evaluated the association between prediction of response to chemotherapy and progression-free interval and overall survival in ovarian cancer.

The CEO of the Ovarian Cancer National Alliance stated that not only are oncologists recognizing the benefits of using chemoresponse assays when faced with equivalent therapeutic options, they are also paving the way for greater support of personalized medicine in oncology.

NCCN Clinical Practice Guidelines in Oncology are developed and updated through an evidence-based process with explicit review of the scientific evidence integrated with expert judgment by multidisciplinary panels of physicians from NCCN member institutions.